Illumina Reports Drop in Preliminary Q3 Revenues | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market on Thursday a drop in preliminary revenues of almost 1 percent year over year for the third quarter.

The San Diego-based firm said that it estimates revenues for the third quarter to come in at around $235 million, compared to $237.3 million from a year ago. That figure also is well below the Wall Street consensus estimate of $277.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.